CALTH. Inc Logo

CALTH. Inc

Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.

402420 | KO

Overview

Corporate Details

ISIN(s):
KR7402420004
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 창업로 54, 321호(시흥동, 기업성장센터), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CALTH Inc. is an in vitro diagnostics (IVD) company that develops and manufactures rapid diagnostic solutions. The company provides innovative healthcare services for point-of-care testing (POCT), self-testing, and precision medicine. Its core business is built upon two proprietary technologies: an "Engineered Nanotrap" system for high-sensitivity sample preprocessing and a deep learning-based algorithm for the rapid and accurate analysis of Lateral Flow Assay products. CALTH's mission is to improve quality of life by delivering fast, accurate, and low-cost diagnostic tools. The company operates in facilities certified with KGMP and ISO 13485:2016.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-11 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-11 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-11 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 82.8 KB
2025-08-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 88.1 KB
2025-08-06 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.2 KB
2025-07-29 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 35.1 KB
2025-07-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.2 KB
2025-07-17 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 54.6 KB
2025-06-19 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.8 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 16.4 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 10.1 KB
2025-03-21 00:00
Annual Report
사업보고서 (2024.12)
Korean 971.9 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 103.1 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 7.5 KB
2025-02-06 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 5.8 KB

Automate Your Workflow. Get a real-time feed of all CALTH. Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CALTH. Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CALTH. Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD

Talk to a Data Expert

Have a question? We'll get back to you promptly.